Poland’s Chief Pharmaceutical Inspector halted the distribution of Lorazepam TZF across the country on March 30, 2026, due to potential quality inconsistencies.
Lorazepam Circulation Suspended Across Poland
The Chief Pharmaceutical Inspector has suspended the circulation of Lorazepam TZF throughout Poland, with the decision taking effect immediately on March 30, 2026. The drug is used to treat anxiety and in emergency medicine.
The decision stems from research indicating a potential quality inconsistency that could affect treatment efficacy. The matter is considered preventative but involves a real risk to treatment effectiveness.
Scope of the Decision
The decision covers two injectable solution products. The suspension prevents further distribution or dispensing of the drug anywhere in Poland.
Reason for Suspension: Low Dosage
Research conducted by the National Institute of Drugs revealed inconsistencies in one quality parameter. Specifically, some ampoules contained a lower-than-specified volume of solution, falling below the acceptable limit.
This means patients may receive a lower dose than intended, potentially reducing treatment effectiveness and raising safety concerns. The manufacturer confirmed the irregularity in repeat testing.
Systemic Suspension: Why All Batches?
Although the research focused on a specific batch, the decision applies to the entire product. This is due to pharmaceutical law, which holds the manufacturer responsible for such risks when introducing a drug to the market.
The suspension is therefore systemic rather than isolated.
Impact on Patients and Hospitals
Lorazepam in injectable form is primarily used in emergency situations and for acute anxiety. Medical facilities must immediately cease its use and find alternative medications.
Short-term local shortages are possible, but alternatives within the same drug class are available.
Manufacturer’s Explanation Rejected
The manufacturer suggested potential errors in specification limits, differing interpretations of results (including rounding), and no issues with the production process, assessing the risk to patients as “low to moderate.”
The GIF rejected these explanations, emphasizing that the existing specification is binding and non-compliance means failing to meet market authorization conditions. Changes require formal approval from the registration authority. The decision was maintained to protect public health.
Right to Appeal and Next Steps
The decision is immediately enforceable, but the manufacturer can still pursue legal options. However, even filing an appeal does not suspend the decision’s execution.
Preventative Measure: Is Lorazepam Dangerous?
The suspension is a preventative measure, not an indication that the drug is dangerous. The key concern is the risk of administering too low a dose, uncertainty about long-term quality stability, and protecting patients from potentially inadequate therapy.
Even minor deviations are significant, especially in drugs used in emergency situations.
Key Questions and Answers for Patients
Is Lorazepam permanently withdrawn? No, circulation is temporarily suspended pending investigation.
Should patients be concerned? The decision is preventative, focusing on dosage effectiveness rather than direct life threats.
Are there alternatives? Yes, other benzodiazepines are available for similar indications.
Can Lorazepam be used at home? Use should be discussed with a doctor, as the decision affects distribution.
